KRAS mutation and wild-type hazard ratios for overall survival and progression-free survival were 1.37 (95% CI, 1.08–1.66), 1.46 (95% CI, 1.15-1.77) in blood samples, and 1.16 (95% CI, 1.03–1.28), 1.28 (95% CI, 1.09–1.46) in tumor tissue. This evidence concerns the gene KRAS and neoplasm.